Enveric Biosciences Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Direxion Daily S&P 500 Bull 3X Shares trades at $273.65. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | SPXL | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $17.40 | $288.04 |
52-Week Low | $1.28 | $170.20 |
Enterprise Value | $408.82K | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPXL, a leveraged ETF tracking the S&P 500, trades at $274.40, down 0.45% today, with a bullish technical signal from moving averages and neutral oscillators. Support levels are at $269 and $271, resistance at $281 and $283. The ETF's performance is tied to S&P 500 movements, with no fundamental ratios available due to its structure. Recent news highlights AI-driven market optimism and earnings season catalysts, but risks include Fed policy and stretched valuations.
Outlook remains tied to S&P 500 trends, with potential upside from AI growth and earnings, but volatility risks from macroeconomic factors and high expectations. Investors should weigh leveraged exposure against market sensitivity.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →